Takeda TYK2 drug tops Bristol Myers’ Sotyktu in psoriasis head-to-head test
100% citation coverage1 regulatory sources
Takeda’s TYK2 inhibitor zasocitinib outperformed Bristol Myers Squibb’s Sotyktu in a head-to-head plaque psoriasis trial. The result strengthens Takeda’s dermatology story and gives BD teams and investors a clearer read on the program’s competitive position.
Intelligence Snapshot
Executive Summary
Takeda's TYK2 inhibitor zasocitinib outperformed Bristol Myers Squibb's Sotyktu in a head-to-head clinical trial for plaque psoriasis, providing a direct comparison against an already-approved benchmark.
Key Insights
-
In the 16-week head-to-head trial, zasocitinib completely eliminated skin lesions in over…
In the 16-week head-to-head trial, zasocitinib completely eliminated skin lesions in over a third of recipients, more than doubling the response seen with Sotyktu.
-
A Phase 3 psoriatic arthritis study (NCT06671483) is currently recruiting , along with…
A Phase 3 psoriatic arthritis study (NCT06671483) is currently recruiting , along with Phase 2 trials in Crohn's disease, ulcerative colitis, and nonsegmental vitiligo.
Market Impact
| Regulatory | low |
|---|---|
| Commercial | high |
| Competitive | high |
| Investment | high |
Takeda's TYK2 inhibitor zasocitinib outperformed Bristol Myers Squibb's Sotyktu in a head-to-head plaque psoriasis trial. The 16-week result showed complete skin-lesion clearance in over a third of recipients, more than doubling the response with Sotyktu.
Loading intelligence…
Quick Answer
Key Questions
- What is zasocitinib, and how does it differ from Sotyktu?
- Is zasocitinib FDA-approved?
- What is Sotyktu's current market position?
- What are the next clinical milestones for zasocitinib?
- What does the psoriasis head-to-head trial result mean for zasocitinib's development?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for zasocitinib.
Unlock full calendar →Takeda pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Contents11 sections
Takeda TYK2 Drug Tops Bristol Myers' Sotyktu in Psoriasis Head-to-Head Test
Key Takeaways
- Takeda's TYK2 inhibitor zasocitinib outperformed Bristol Myers Squibb's Sotyktu in a head-to-head clinical trial for plaque psoriasis, providing a direct comparison against an already-approved benchmark.
- In the 16-week head-to-head trial, zasocitinib completely eliminated skin lesions in over a third of recipients, more than doubling the response seen with Sotyktu.
- A Phase 3 psoriatic arthritis study (NCT06671483) is currently recruiting, along with Phase 2 trials in Crohn's disease, ulcerative colitis, and nonsegmental vitiligo.
IntelligenceCompetitive Intelligence
Competitive pressure is high. Takeda and Bristol Myers Squibb reshape positioning, formulary leverage, and partnership options. Benchmark pipeline differentiation and regional market access assumptions against this development.
Clinical Head-to-Head Result
Takeda's TYK2 inhibitor zasocitinib outperformed Bristol Myers Squibb's Sotyktu in a head-to-head clinical trial for plaque psoriasis. The trial directly compared the two oral tyrosine kinase 2 inhibitors, a comparison that matters because Sotyktu is already FDA-indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, making it an established benchmark in the dermatology market.
After 16 weeks, zasocitinib completely eliminated skin lesions in over a third of recipients, more than doubling the response seen with Sotyktu.
IntelligenceMarket Signals
Commercial pull is high and investment relevance high for psoriasis. Hospital consolidation and provider M&A can shift formulary control and regional contracting — recalibrate forecasts accordingly.
Regulatory Context: Sotyktu's Current Position
Sotyktu (deucravacitinib) is a tyrosine kinase 2 inhibitor indicated for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. The drug also carries an indication for active psoriatic arthritis in adults, giving Bristol Myers a dual-indication foothold in the TYK2 space. Takeda's head-to-head result against an already-approved competitor provides a clinical comparison point but does not yet confer regulatory approval or labeling advantage without FDA review.
IntelligenceStrategic Takeaways
Takeda's TYK2 inhibitor zasocitinib outperformed Bristol Myers Squibb's Sotyktu in a head-to-head clinical trial for plaque psoriasis, providing a direct comparison against an already-approved benchmark. In the 16-week head-to-head trial, zasocitinib completely eliminated skin lesions in over a third of recipients, more than doubling the response seen with Sotyktu. A Phase 3 psoriatic arthritis study (NCT06671483) is
Ongoing Zasocitinib Clinical Trials
A Phase 3 study in adults with psoriatic arthritis who have not taken biologic medicines (NCT06671483) is currently recruiting. A Phase 2 study in adults with active Crohn's disease (NCT07403968) is not yet recruiting.
A Phase 2 continuation study in adults with ulcerative colitis and Crohn's disease (NCT06764615) is currently recruiting. Additional trials include a Phase 2 study in nonsegmental vitiligo (NCT07108283) and a Phase 2 study evaluating safety and inflammation reduction in moderate-to-severe Crohn's disease (NCT06233461), both recruiting.
IntelligenceEvidence Quality
Grounded in 1 regulatory source.
What to Watch Next
Upcoming data readouts from ongoing trials will include results from the psoriatic arthritis Phase 3 trial (NCT06671483), which is actively recruiting. Progress updates on the inflammatory bowel disease continuation study (NCT06764615) and the Crohn's disease Phase 2 trial (NCT07403968) will provide additional clinical data.
Trial Snapshot
| Trial | Title | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT07403968 | A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease | NOT_YET_RECRUITING | PHASE2 | Takeda |
| NCT06671483 | A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | RECRUITING | PHASE3 | Takeda |
| NCT06764615 | A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD) | RECRUITING | PHASE2 | Takeda |
| NCT07108283 | A Study of Zasocitinib in Adults With Nonsegmental Vitiligo | RECRUITING | PHASE2 | Takeda |
| NCT06233461 | A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease | RECRUITING | PHASE2 | Takeda |
Timeline
- Takeda 6-K (2026-06-09)
- Takeda 6-K (2026-06-05)
- Takeda 6-K (2026-06-05)
- Takeda 6-K (2026-06-01)
- Takeda 6-K (2026-05-26)
- Not_Yet_Recruiting trial NCT07403968 (PHASE2)
- Recruiting trial NCT06671483 (PHASE3)
- Recruiting trial NCT06764615 (PHASE2)
- Recruiting trial NCT07108283 (PHASE2)
- Recruiting trial NCT06233461 (PHASE2)
Frequently Asked Questions
What is zasocitinib, and how does it differ from Sotyktu?
Both zasocitinib and Sotyktu are tyrosine kinase 2 (TYK2) inhibitors. In a head-to-head trial, zasocitinib demonstrated superior efficacy, with complete skin-lesion clearance in over a third of patients after 16 weeks, compared to a lower response rate with Sotyktu. Both are oral agents.
Is zasocitinib FDA-approved?
No. Zasocitinib is not yet FDA-approved. It is currently in clinical development across multiple indications including plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and nonsegmental vitiligo. Regulatory approval would require submission of clinical data to the FDA and a successful review process.
What is Sotyktu's current market position?
Sotyktu (deucravacitinib) is FDA-indicated for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, and for active psoriatic arthritis in adults. It is an approved oral TYK2 inhibitor already in clinical use.
What are the next clinical milestones for zasocitinib?
A Phase 3 study in psoriatic arthritis (NCT06671483) is currently recruiting. Phase 2 trials in inflammatory bowel disease and nonsegmental vitiligo are also active. Completion and unblinding of these trials will provide additional efficacy and safety data.
What does the psoriasis head-to-head trial result mean for zasocitinib's development?
The head-to-head trial result provides clinical data on zasocitinib's efficacy relative to an approved competitor in plaque psoriasis. A single trial result does not guarantee regulatory approval, market adoption, or revenue success. The outcome contributes to the clinical evidence base for the asset.
Related profiles
Related coverage
Continue Exploring
Jump into the entities behind this story.
Ask AI About psoriasis
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow zasocitinib developments
FDA psoriasis alerts and zasocitinib pipeline updates, every Monday.
- Sources analyzed
- 1
- Evidence strength
- 91/100
- Last verified
- Jun 11, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Critical source quality · grounded in cited primary and secondary sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
